Wyeth Korea Products Wyeth Korea is a pharmaceutical company concentrating on prescription and treatment medicines. Its representative items include hormones, vaccines, anti-depression agents, antibiotics and anti-inflammation enzymes. It is expected that hormone replacement therapy (HRT) agents for women after the menopause will be the item to exceed the net sales of 10 billion won for the first time for Wyeth Korea. The main products are Premarin and Premelle.
Premarin tablets are the only natural combination-type estrogen preparation approved by the American FDA. They are used by more than 50 million women throughout the world since they cure diseases of the vascular movement system and urological system of women during menopause and are very effective for the prevention and treatment of osteoporosis and cardiac diseases. The vaccine, HibTITER , which is a preventive vaccine for cerebral meningitis, is representative and effective for the prevention of inflammatory disease by hemophilus influenza b type in 2- to 71-month-old infants and children. Also, Efexor and Efexor XR, which are the first anti-depression agents in the SNRI group, have infinite potential to grow since they are characterized by excellent safety, low-tolerant drug interaction. Furthermore, the company owns 24 prescription and treatment medicines including Tazocin(Piperacillin/Tazobactam) which is evaluated to be the most recent and remarkable drug in the β-lactamase inhibitor group in the domestic antibiotics market, Novantrone which is a leading anti-cancer drug, aridase Varidase which is an extensive anti-inflammation enzyme, Materna-Beta which is a composite hemotogenous nutrient for pregnant women and nursing mothers. All of these have the potential to grow as expected by Wyeth Korea, Inc.

Still further, the company is preparing for introduction of epoch-making new drugs sooner or later such as Enbrel which is an innovating rheumatoic arthritis treatment agent, Prevenar which is a vaccine for pneumonia mictococci in newly born infants, ReFacto which is a gene recombinant blood coagulation factor for the treatment of leukemia, Rapamune which is an immunization suppressing agent for the prevention of tissue rejection for organ transplantations.